Formulation development and Evaluation of Floating tablets containing Alogliptin using different polymers

Abstract

Formulation F3, comprising of CAB: PEO (80: 20 wt percent) with 1.5 wt percent PVA solution and drug loading (10 wt percent), demonstrated the best entrapment (87.0 and 21.06%) and release (Q12h=78.19 and 0.90%) values in simulated stomach fluid pH 1.2 when compared to other compositions. The microspheres prefer to float over the simulated stomach media for over ten hours. It was discovered that the microspheres' percent buoyancy may reach 89.50 and 1.53%, which suggests that the drug was administered in a gastroretentive way. Stability investigations showed that the particle size distribution and shape of formulation F3 had changed somewhat after one month of storage at 40.2°C and 75% relative humidity. This suggests that formulations were stable under accelerated storage conditions. As a result, efforts were made in the current study to formulate and evaluate CAB and PEO blend microspheres for the gastroretentive floating drug delivery of an antidiabetic drug such as alogliptin using an emulsion solvent evaporation technique with various polymer concentrations in order to improve the drug's short biological half-life and gastric retention time. This study showed that a combination of two hydrophilic and biocompatible polymers, cellulose acetate butyrate (CAB) and polyethylene oxide (PEO), may be used to make floating microspheres for the efficient and successful integration of alogliptin using an emulsion solvent evaporation approach. The production of a blend of this formulation revealed superior floating capabilities than separate polymers, indicating that blend formation is suitable for the preparation of microspheres.